share_log

AbbVie's (NYSE:ABBV) Five-year Earnings Growth Trails the 20% YoY Shareholder Returns

AbbVie's (NYSE:ABBV) Five-year Earnings Growth Trails the 20% YoY Shareholder Returns

艾伯維公司(紐交所:ABBV)五年收益增長落後於20%的年股東回報。
Simply Wall St ·  00:53

When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far more than 100% on a really good stock. For example, the AbbVie Inc. (NYSE:ABBV) share price has soared 100% in the last half decade. Most would be very happy with that. And in the last week the share price has popped 4.5%. But this could be related to the buoyant market which is up about 2.8% in a week.

當你購買股票時,總是存在它可能會下跌100%的可能性。但從積極的一面來看,你在一隻真正優秀的股票上可以賺得遠超過100%。例如,艾伯維公司(紐交所:ABBV)的股價在過去五年間飆升了100%。大多數人對此會非常高興。而在過去一週內,股價上漲了4.5%。但這可能與市場的上漲有關,市場在一週內上升了約2.8%。

Since it's been a strong week for AbbVie shareholders, let's have a look at trend of the longer term fundamentals.

由於這一週對艾伯維公司的股東來說非常強勁,讓我們來看看長期基本面的趨勢。

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

雖然市場是一個強大的定價機制,但股價反映的卻是投資者情緒,而不僅僅是基礎業務表現。一種不完美但簡單的考慮收入每股收益(EPS)變化與股價變動的市場認知變化的方法是比較它們之間的差異。

Over half a decade, AbbVie managed to grow its earnings per share at 5.7% a year. This EPS growth is slower than the share price growth of 15% per year, over the same period. This suggests that market participants hold the company in higher regard, these days. That's not necessarily surprising considering the five-year track record of earnings growth. This optimism is visible in its fairly high P/E ratio of 62.32.

在過去五年中,艾伯維每年設法將每股收益增長5.7%。這一EPS增長低於同期股價每年15%的增長。這表明市場參與者現在更加看重該公司。這並不令人驚訝,考慮到五年來的盈利增長記錄。這種樂觀情緒在其較高的市盈率62.32中可見一斑。

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

下圖顯示了EPS隨時間變化的情況(點擊圖像以顯示確切值)。

big
NYSE:ABBV Earnings Per Share Growth December 27th 2024
紐交所:艾伯維公司每股收益增長 2024年12月27日

Dive deeper into AbbVie's key metrics by checking this interactive graph of AbbVie's earnings, revenue and cash flow.

通過查看艾伯維公司的收益、營業收入和現金流的互動圖表,深入了解艾伯維公司的關鍵指標。

What About Dividends?

關於分紅派息的問題

As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of AbbVie, it has a TSR of 148% for the last 5 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return.

除了衡量股價回報外,投資者還應考慮總股東回報(TSR)。TSR考慮了任何剝離或折扣資本籌集的價值,以及任何分紅,基於分紅被再投資的假設。可以公平地說,TSR爲支付分紅的股票提供了更全面的概述。以艾伯維公司爲例,它在過去5年內的TSR爲148%。這超過了我們之前提到的股價回報。公司支付的分紅因此提升了總股東回報。

A Different Perspective

不同的視角

AbbVie shareholders gained a total return of 20% during the year. But that was short of the market average. On the bright side, that's still a gain, and it's actually better than the average return of 20% over half a decade This could indicate that the company is winning over new investors, as it pursues its strategy. It's always interesting to track share price performance over the longer term. But to understand AbbVie better, we need to consider many other factors. Even so, be aware that AbbVie is showing 3 warning signs in our investment analysis , you should know about...

艾伯維公司的股東在一年內獲得了20%的總回報。但這低於市場平均水平。值得慶幸的是,這仍然是一個增益,實際上比過去五年半的平均回報20%要好。這可能表明公司在贏得新的投資者,正追求其策略。長期跟蹤股價表現總是很有趣。但要更好地理解艾伯維,我們需要考慮許多其他因素。即便如此,請注意,艾伯維在我們的投資分析中顯示出3個警告信號,你應該了解...

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

當然,你可能會通過其他地方尋找一個絕佳的投資機會。所以請查看這個我們預計將增長每股收益的公司免費列表。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文中引用的市場回報反映了當前在美國交易所上市股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論